<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3150">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04457505</url>
  </required_header>
  <id_info>
    <org_study_id>CIBERESUCICOVID</org_study_id>
    <nct_id>NCT04457505</nct_id>
  </id_info>
  <brief_title>One Year Follow-ups of Patients Admitted to Spanish Intensive Care Units Due to COVID-19</brief_title>
  <official_title>Risk Factors, Personalized Prognoses and 1-year Follow-ups of Patients Admitted to Spanish Intensive Care Units Due to COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Consorcio Centro de Investigación Biomédica en Red, M.P.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barcelona Supercomputing Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carlos III Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Consorcio Centro de Investigación Biomédica en Red, M.P.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The latest epidemiological data published from Chine reports that up to 30% of
      hospital-admitted patients required admission to intensive care units (ICU). The cause for
      ICU admission for most patients is very severe respiratory failure; 80% of the patients
      present with severe acute respiratory distress syndrome (SARS) that requires protective
      mechanical ventilation.

      Five percent of patients with SARS require extracorporeal circulation (ECMO) techniques.
      Global mortality data has been thus far reported in different individual publications from
      China. Without accounting for those patients still admitted to hospital, bona fide
      information (from a hospital in Wuhan) received by the PI of this project estimates that
      mortality of hospitalized patients is more than 10%. Evidently, mortality is concentrated in
      patients admitted to the ICU and those patients who require mechanical ventilation and
      present with SARS. As data in China was globally reported, risk factors and prognosis of
      patients with and without SARS who require mechanical ventilation are not definitively known.
      The efficacy of different treatments administered empirically or based on small, observation
      studies is also not known. With many still admitted at the time of publication, a recent
      study in JAMA about 1500 patients admitted to the ICU in the region of Lombardy (Italy)
      reported a crude mortality rate of 25%. The data published until the current date is merely
      observational, prospective or retrospective. Data has not been recorded by analysis performed
      with artificial intelligence (machine learning) in order to report much more personalized
      results. Furthermore, as it concerns patients admitted to the ICU who survive, respiratory
      and cardiovascular consequences, as well as quality of living are completely unknown.

      The study further aims to investigate quality of life and different respiratory and
      cardiovascular outcomes at 6 months, as well as crude mortality within 1 year after discharge
      of patients with COVID-19 who survive following ICU admission. Lastly, with the objective to
      help personalize treatment in accordance with altered biological pathways in each patient,
      two types of studies will be performed: 1) epigenetics and 2) predictive enrichment of
      biomarkers in plasma.

      Hypothesis

        -  A significant percentage of patients (20%) admitted to the hospital with COVID-19
           infection is expected to require ICU admission, and need mechanical ventilation (80%)
           and, in a minor percentage (5%), ECMO.

        -  Patients who survive an acute episode during ICU hospitalization will have a yearly
           accumulated mortality of 40%. Those who then survive will have respiratory consequences,
           cardiovascular complications and poor quality of life (6 months).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective and Purpose of Study

        1. The main objective is to determine risks factors and prognosis of patients with COVID-19
           infection who have been admitted to Spanish ICUs between the beginning and end of the
           pandemic in Spain. Special attention will be placed on identifying differential
           expression of prognostic factors based on sex.

        2. The second objective is to perform a follow-up of patients within 6 months after
           discharge from ICU and hospital in order to determine mortality (including at 1-year
           mark), functional respiratory and cardiovascular consequences, and quality of life.

        3. The third objective is to perform an epigenetic study in cases, in which a blood sample
           can be drawn. The aim of such undertaking is to define molecular signatures in liquid
           biopsies that can provide information regarding prognosis, and treatment monitoring and
           response to therapy.

        4. Lastly, predictive ability of response to therapy and mortality will be assessed from a
           panel of protein biomarkers that participate in key physiological pathways of the
           disease's pathogenesis. This could, in turn, help select prospective treatments with
           greater potential of being successful in each patient.

      Principal and Secondary Variables

        1. Prior epidemiological data of the patient

        2. Biological and clinical data, including treatment administered upon hospital admission

        3. Biological and clinical data, including treatments administered upon and during ICU
           admission until either discharge from ICU or hospital, or death

        4. Specific data regarding artificial ventilation and ECMO since the beginning, as well as
           sequentially, from intubation to either extubation or death

        5. Biological and clinical data upon hospital discharge

        6. Clinical follow-up of patients who survive within 6 months, including: functional
           respiratory tests, echocardiograms and surveys regarding quality of life

        7. Intrahospital and intra-ICU mortality will be registered at 28- and 90-day marks, as
           well as within 6 months and 1 year

        8. 1000 blood samples will be drawn for the epigenetic study The molecular profile of a
           non-coding RNA (ncRNA), specifically the microRNA (miRNA) pattern in liquid biopsy, will
           be analyzed. A circulating miRNA signature is closer to the phenotype than genomic
           markers and can provide information regarding epigenetic regulation, cell activation,
           tissue repair, and metabolic processes in addition to that afforded by clinical
           predictors and classic risk factors. miRNAs offer appropriate biochemical properties
           that are highly stable; have a long half-life in biological samples used in clinical
           laboratories (serum/plasma); can be efficiently and relatively rapidly quantified with
           high sensitivity and specificity by RT-qPCR; and can serve as a profitable tool for the
           assessment of risks and disease control.

      All of these characteristics have led distinct authors to propose the clinical application of
      miRNA in either the short or medium term.

      The experimental design comprises two phases. In the first approximation, a screening of
      non-coding RNA (ncRNA) will be performed in a sub-population of patients (n=200). The number
      of samples surpasses the quantity recommended for this type of studies. (Schurch y cols.,
      RNA, 2016). A quotation will be requested for the screening of ncRNA by HTG EdgeSeq miRNA
      Whole Transcriptome Assay system (HTG). Using next generation sequencing (NGS), this method
      allows for the quantification of 2083 human candidates. All of the procedure steps will be
      completed in suitable physical locations in accordance with code OP No. 0028. All of the
      samples will be prepared in accordance with code No. 0036.

      Screening results will be validated in the validation cohort (n=800) with RT-qPCR, a
      gold-standard technique. The budget includes material necessary for RNA extraction (miRNeasy
      Serum/Plasma isolation kits, Qiagen; spike-in; carrier RNA; consumables) and expression
      quantification of ncRNA in biofluids (RT-qPCR miRCURY LNA Universal RT microRNA PCR System
      kits, Qiagen; endogenous controls; consumables. Studies will be carried out at the TRRM Group
      facilities in the IRBLleida. The laboratory has the necessary team and material to isolate
      and quantify RNA, and store reagents and samples (cold stores, freezers of 20ºC and -80ºC).

      9.- For the study of prognostic biomarkers, concentration of biomarkers in plasma that are
      key to potentially useful drugs' mechanism of action in this disease will be assessed. This
      quantification could provide guidance on drug usage (lymphocyte count will be obtained from a
      blood count):
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>One year mortality</measure>
    <time_frame>At 12 months of ICU admission</time_frame>
    <description>People who died after one year of follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Six month mortality</measure>
    <time_frame>At 6 month of ICU admission</time_frame>
    <description>People who died after one year of follow up</description>
  </primary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Severe Pneumonia</condition>
  <condition>Respiratory Failure</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      For the epigenetic study, blood samples will be gathered from 1000 patients within 48 hours
      after admission to the ICU. The collection and preparation of plasma samples will be done in
      accordance with Early Detection Research Network (EDRN) Standard Operating Procedures
      (National Cancer Institute, USA).

      For the study of prognostic biomarkers, concentration of biomarkers in plasma that are key to
      potentially useful drugs' mechanism of action in this disease will be assessed. Plasma
      samples will be collected from 1000 patients within 48 hours after admission to the ICU.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to Spanish ICUs.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Laboratory-confirmed COVID-19 infection with either real-time PCR or Next
             Generation Sequencing (NGS)

          -  2. Admission to intensive care unit

        Exclusion Criteria:

          -  1. Patients admitted to COVID-19-negative ICU
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoni Torres, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spanish Research Center for Respiratory Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrian A Ceccato, PhD.</last_name>
    <phone>+34932275400</phone>
    <phone_ext>2015</phone_ext>
    <email>aceccato@clinic.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>30011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Muñiz, MD</last_name>
      <phone>+34669 463 486</phone>
      <email>guillermo.muniz@sespa.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Máñez Mendiluce</last_name>
      <phone>+34932607646</phone>
      <email>rmanez@bellvitgehospital.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Mataró</city>
        <state>Barcelona</state>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mari C de la Torre, MD</last_name>
      <phone>+34652137678</phone>
      <email>mctorre@csdm.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Cataluña</name>
      <address>
        <city>Sant Cugat Del Vallès</city>
        <state>Barcelona</state>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria L Martinez, MD</last_name>
      <phone>+34620 725139</phone>
      <email>makilu80@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Margarita de Cabra</name>
      <address>
        <city>Cabra</city>
        <state>Córdoba</state>
        <zip>14940</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Lara, MD</last_name>
      <phone>+34661496874</phone>
      <email>pedro.lara.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <state>Galicia</state>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Martinez</last_name>
      <phone>+34697434141</phone>
      <email>ignacioyag.martinez@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Mallorca</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Socías Crespí, MD</last_name>
      <phone>+34619 856 936</phone>
      <email>lsocias@hsll.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36213</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Vila Fernández, MD</last_name>
      <email>dolores.vila.fernandez@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Verge de la Cinta</name>
      <address>
        <city>Tortosa</city>
        <state>Tarragona</state>
        <zip>43500</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferran Roche, MD</last_name>
      <phone>+34657135030</phone>
      <email>ferranroche@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Sant Joan d'Alacant</name>
      <address>
        <city>Alicante</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Sanchez</last_name>
      <phone>+34647832317</phone>
      <email>an.sanchezm1@coma.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Sagrada Família</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arturo Huerta Garcia, MD</last_name>
      <phone>+34679788559</phone>
      <email>ahuerta@clinicasagradafamilia.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sagrat Cor</name>
      <address>
        <city>Barcelona</city>
        <zip>08029</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrián Ceccato, MD</last_name>
      <phone>+34666610816</phone>
      <email>adrianceccato@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Riera, MD</last_name>
      <email>jorriera@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital, Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricard Ferrer, MD</last_name>
      <phone>+34637 369 713</phone>
      <email>r.ferrer@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoni Torres</last_name>
      <phone>+34670659745</phone>
      <email>atorres@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Ossa, MD</last_name>
      <phone>+34677 804 636</phone>
      <email>ossasergio@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Gallego, MD</last_name>
      <phone>+34665516880</phone>
      <email>elenagallegocurto@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>León</city>
        <zip>24008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Demetrio Carriedo, MD</last_name>
      <phone>+34669 34 25 78</phone>
      <email>dcarriedo@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús Caballero, MD</last_name>
      <phone>+34686529608</phone>
      <email>jcaballero.lleida.ics@gencat.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amalia MARTINEZ DE LA GÁNDARA, MD</last_name>
      <phone>+34 911 91 80 00</phone>
      <email>amartinezga@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José M Añon Elizalde, MD</last_name>
      <phone>+34620152794</phone>
      <email>jmaelizalde@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Ourense</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Vidal Cortes, MD</last_name>
      <phone>+34692140699</phone>
      <email>pablo.vidal.cortes@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Palencia</name>
      <address>
        <city>Palencia</city>
        <zip>34005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan López Messa, MD</last_name>
      <phone>+34667025344</phone>
      <email>jlomessa@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Montecelo</name>
      <address>
        <city>Pontevedra</city>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Ortega Montes, MD</last_name>
      <phone>+34986 800 398</phone>
      <email>anaortegamontes@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Sagredo, MD</last_name>
      <phone>+34660 301 738</phone>
      <email>vsagredo@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Loza, MD</last_name>
      <phone>+34955015593</phone>
      <email>aloza@telefonica.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Tarragona Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro Rodriguez, MD</last_name>
      <phone>+34626 179 726</phone>
      <email>ahr1161@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic Universitari de València</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nieves Carbonell, MD</last_name>
      <phone>+34679841833</phone>
      <email>edurnecarbonell@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Sancho, MD</last_name>
      <phone>+34677984787</phone>
      <email>sancho_sus@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena BUSTAMANTE MUNGUIRA, MD</last_name>
      <phone>+34630 355 073</phone>
      <email>ebustamante@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Gracia</name>
      <address>
        <city>Zaragoza</city>
        <zip>50004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Jorge Garcia</last_name>
      <phone>+34609 87 96 03</phone>
      <email>ruthjorge@telefonica.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD anonymized that underlie results in a publication will be available after publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After publication</ipd_time_frame>
    <ipd_access_criteria>Data will be available after reasoning requested.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

